CAJ | 학술논문

目的：了解广州中医药大学第一附属医院2011～2013年临床分离的鲍曼不动杆菌标本来源和科室来源的分布及对各类抗菌药物的耐药性，以指导临床规范用药及防止耐药性增加。方法按统一方案、采用统一的材料、方法和判断标准（CLSI2010年版）进行鲍曼不动杆菌耐药性监测。结果579株鲍曼不动杆菌中，2011年分离到39株（占2.2％），2012年187株（占10.5％），2013年353株（占15.4％）。科室分布情况，以 ICU（271株）、呼吸科（104株）为主。各类标本分离阳性率来看，以痰（5.55％）为主，其次是伤口分泌物、脓液。耐药情况，头孢哌酮／舒巴坦耐药率（40.1％）最低，可作为首选药物之一。结论鲍曼不动杆菌对多种抗菌药物耐药率高，临床应加强对鲍曼不动杆菌耐药性监测，合理选用抗菌药物。
목적：료해엄주중의약대학제일부속의원2011～2013년림상분리적포만불동간균표본래원화과실래원적분포급대각류항균약물적내약성，이지도림상규범용약급방지내약성증가。방법안통일방안、채용통일적재료、방법화판단표준（CLSI2010년판）진행포만불동간균내약성감측。결과579주포만불동간균중，2011년분리도39주（점2.2％），2012년187주（점10.5％），2013년353주（점15.4％）。과실분포정황，이 ICU（271주）、호흡과（104주）위주。각류표본분리양성솔래간，이담（5.55％）위주，기차시상구분비물、농액。내약정황，두포고동／서파탄내약솔（40.1％）최저，가작위수선약물지일。결론포만불동간균대다충항균약물내약솔고，림상응가강대포만불동간균내약성감측，합리선용항균약물。
Objective To understand the specimen source of clinical isolated Acinetobacter(A.)baumannii and its department distribution and drug resistance in order to guide the clinical standardized medication for preventing the drug resistance increase. Methods The drug resistance of A.baumannii was monitored by using the unified scheme,materials,methods and criteria (CLSI2010).Results Among 579 strains of A.Baumannii,39 strains(2.2%)were isolated in 2011,187 strains(10.5%)were isola-ted in 2012 and 353 strains(15.4%)were isolated in 2013.In the department distribution,271 strains were isolated from ICU and 104 strains from the department of respiratory medicine.In the positive isolation rates of various specimens,the positive rate was dominated by the sputum specimen(5.55%),followed by wound secretion and pus.The antibacterial susceptibility tests showed that A.baumannii had lowest resistance to cefoperazone/sulbactam(40.1%),which could be used as the drug of first choice.Con-clusion A.baumannii has the higher resistance to many kinds of antibacterial drugs.The drug resistance monitoring of A.bauman-nii should be strengthened in clinc and antibacterial drugs should be selected and used rationally.